GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Valuation Rank

SSY Group (HKSE:02005) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is SSY Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

SSY Group Valuation Rank Related Terms

Thank you for viewing the detailed overview of SSY Group's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

SSY Group (HKSE:02005) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Valuation Rank
Comparable Companies
HKSE:02096 HKSE:00512 HKSE:03933 HKSE:01558 HKSE:06600 HKSE:00867 HKSE:02186 HKSE:06185 HKSE:03613 HKSE:02877 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
Website
http://www.ssygroup.com.hk
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.